Filing of Registration Statement Proposed US IPO

 

TIDMMEDG 
 
RNS Number : 7654V 
Medgenics Inc 
08 November 2010 
 

 
8 November 2010 
                                Medgenics, Inc. 
                         ("Medgenics" or the "Company") 
 
Medgenics Announces Filing of Registration Statement for Proposed Initial Public 
                                    Offering 
                        of its Common Stock in the U.S. 
 
Misgav, Israel and London, UK -8 November 2010 - Medgenics, Inc. (AIM: MEDG, 
MEDU), today announced the filing of a registration statement on Form S-1 with 
the U.S. Securities and Exchange Commission ("SEC") for the proposed initial 
public offering of its common stock in the U.S.. The number of shares of common 
stock to be offered and the price range for the offering have not yet been 
determined.  Roth Capital Partners, LLC and Maxim Group LLC are acting as 
representatives of the underwriters in the offering. 
A registration statement relating to the shares of common stock has been filed 
with the SEC but has not yet become effective.  The shares of common stock to be 
sold in the offering may not be sold, nor may any offers to buy be accepted, 
prior to the time the registration statement becomes effective.  This release 
shall not constitute an offer to sell or the solicitation of an offer to buy nor 
shall there be any sale of these securities in any state or jurisdiction in 
which such offer, solicitation or sale would be unlawful prior to registration 
or qualification under the securities laws of any such state or jurisdiction. 
Sales of common stock under the registration statement cannot occur until it is 
declared effective by the U.S. Securities and Exchange Commission,  There can be 
no assurance as to if and when the Securities and Exchange Commission will 
declare the Company's registration statement effective.  The registration 
statement is available at the U.S. Securities and Exchange Commission's website 
at www.sec.gov. 
 
This offering of common stock will be made only by means of a prospectus.  When 
available, a written prospectus meeting the requirements of Section 10 of the 
Securities Act of 1933, as amended, may be obtained from Roth Capital Partners, 
LLC at 24 Corporate Plaza Dr., Newport Beach, CA 92660, attention: Equity 
Capital Markets or 800-678-9147 or from Maxim Group LLC at 405 Lexington Avenue, 
New York, New York 10174 or 800-724-0761. 
 
For further information, contact: 
 
+----------------------------------+--------------------------+ 
| Medgenics, Inc.                  | Phone: [phone]   | 
| Dr. Andrew L. Pearlman           |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| De Facto Communications          | Phone: [phone]  | 
| Mike Wort                        |                          | 
| Anna Dunphy                      |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| Religare Capital Markets (Nomad) | Phone: [phone]  | 
| James Pinner                     |                          | 
| Derek Crowhurst                  |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| SVS Securities plc (Joint        | Phone: [phone]  | 
| Broker)                          |                          | 
| Alex Mattey                      |                          | 
| Ian Callaway                     |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| Nomura Code Securities (Joint    | Phone: [phone]  | 
| Broker)                          |                          | 
| Jonathan Senior                  |                          | 
|                                  |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUWVNRRWAARRA